Abstract
The 2019 coronavirus disease (COVID-19) is now a global pandemic. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative pathogen of COVID-19. Here, we study an in-host model that highlights the effector T cell response to SARS-CoV-2. The stability of a unique positive equilibrium point, with viral load suggests that the virus may replicate fast enough to overcome T cell response and cause infection. This overcoming is the bifurcation point, near which the orders of magnitude for can be sensitive to numerical changes in the parameter values. Our work offers a mathematical insight into how SARS-CoV-2 causes the disease.
Keywords: COVID-19, SARS-CoV-2, In-host model, Effector T cell response, Bifurcation
1. Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the official name given to the virus behind the 2019 coronavirus disease (COVID-19) [1]. This pathogen is now the cause of a global pandemic, which began late December 2019 in Wuhan, China [2], [3], [4]. As of October 25, 2020, World Health Organization and the European CDC estimates are at least 42 million confirmed cases and 1.1 million deaths. The health, economic, and social impacts of the coronavirus pandemic have urged worldwide action [5], [6], [7].
Several SIR type epidemiological mathematical models have been proposed to assist policy makers in order to infer disease-control interventions [8], [9], [10], as well as tools to track epidemic trajectories (e.g., [7]) have been widely developed. While potential vaccines and antiviral drugs are under investigation [2], [11], [12], epidemiological models have underlined the relevance of social distancing interventions as the main weapon so far to mitigate the epidemic.
Previous coronavirus outbreaks in Asia 2003 (SARS-CoV) and in Saudi Arabia 2012 (MERS-CoV) have uncovered similar aspects to SARS-CoV-2. For example, viral dynamics in patients with MERS-CoV [13] showed that viral levels peak during the second week with a median value of 7.21 (log10 copies/mL) in the severe patient group, and about 5.54 (log10 copies/mL) in the mild group. In patients with SARS, the virus peaked at 5.7 (log10 copies/mL) between 7 to 10 days after onset [14]. For COVID-19, the viral peak was approximately 8.85 (log10 copies/mL) before 5 days post symptoms onset (dpso) [15]. COVID-19 patients with severe disease reported a mean viral load on admission 60 times higher than that of the mean of mild disease cases, implying that higher viral loads relate clinical outcomes [16]. Furthermore, viral load persisted for 12 days after onset [16].
T cell responses play a key aspect for the management of the current COVID-19 pandemic. Lymphocyte subsets and cytokine profiles in the peripheral blood in [17] showed that the severe COVID-19 patients compared to those in the mild cases had significant decrease in T cell levels, especially CD8+ T cells, as well as increases in IL-6, IL-10, IL-2 and IFN- levels. In fact, recent studies [18] have suggested that pre-existing T cells present in the general population impact susceptibility and pathogenesis of SARS-CoV-2 infection. Another critical aspect of the immune systems is the B cell responses. A prospective cohort with COVID-19 patients in [19] showed that IgM started on day 7 while that of IgG was on day 10 and day 49 after illness onset. IgM and IgG titers are significantly higher in severe patients than non-severe patients. Ultimately, a collection of studies found that COVID-19 disease involves a range of biological mechanisms, including cellular-membrane entry points, elevated pro-inflammatory levels, and activation of immune cells—see, e.g., [12], [20], [21] for a review.
Bringing together the pathogenesis and the immune responses to COVID-19 are still needed. Mathematical models may provide conceptual frameworks to study immune responses to SARS-CoV-2 dynamics. At the moment, there are too few modeling efforts at the within-host level of the COVID-19 disease. The study in [22] employed a target cell model to estimate infection parameter values based on chest radiograph scoring system [23], [24]. However, this model assumed the immune response as an implicit constant value contributing to the death of infected host cells. The study in [25] provided different mechanistic models to represent SARS-CoV-2 dynamics in patients with COVID-19. Among the different mathematical models in [25], the model with the best fit to viral load data presented in [26] prioritizes self-limiting viral replication and effector T cell responses, which may peak between 5 to 10 days post onset of symptoms. The models in [22] and [25] progressed our knowledge in SARS-CoV-2 dynamics, however there were no further stability analysis. Because of the importance to advance our understanding of how the immune system responds to SARS-CoV-2 [27], [28], we study the mathematical model in [25] with effector T cell responses.
Our paper is organized as follows. The model describing SARS-CoV-2 dynamics and its respective bifurcation analysis is presented in Section 2, which characterizes the stability of the virus-free equilibrium point. Subsection 2.2 establishes the stability of a unique positive equilibrium point. Sensitivity analysis of the within-host model is introduced in Section 3. Discussions are presented in Section 4, where we provide insight into the results supported by numerical examples.
2. Bifurcation analysis
The model proposed in [25] that focuses on effector T cell responses is given by
| (1) |
| (2) |
where is the number of effector T cells, and is the density of SARS-CoV-2 (log10 copies/mL). The underlying assumption in this model is that viral clearance is mainly driven by T cell response, this observation is based on different viral infections [29]. Here, the viral replication rate is (1/day), maximum carrying capacity is (log10 copies/mL), and viral clearance rate is (1/day). Without infection, effector T cells remain to the homeostatic level (initial number of T cells), where (cells/day) and (1/day) are the homeostatic generation rate and the half-life of T cells, respectively. The activation of T cells during infection is represented with the term where
| (3) |
and (1/day) is the maximum activation rate. The term reflects the elimination of the virus by T cells with rate (per T cell per day). The activation function satisfies
| (4) |
Two values control the rate of increase of namely the coefficient (dimensionless) and the half-saturation constant (log10 copies/mL). The units for and render a dimensionless quantity.
The modeling work in [25] assumed a log-sigmoidal form of T cell activation, i.e., with . To allow for generality of our results, we can assume any bounded function that satisfies (4). Complementing our analysis are numerical results using different sets of parameter values in Table 1.
Table 1.
Sets of parameter values generated in [25] by model fitting with patient data from [26]. Each of the sets A to I corresponds to a set of patient data, while the Set Mean provides the mean of the parameter estimates. All sets assume that .
| Set | ||||
|---|---|---|---|---|
| A | 5.89 | 1.58 | ||
| B | 0.76 | 1.6 | ||
| C | 0.18 | 1.99 | ||
| D | 0.52 | 1.58 | ||
| E | 0.37 | 1.58 | ||
| F | 25.7 | 1.58 | ||
| G | 0.43 | 1.58 | ||
| H | 0.39 | 1.99 | ||
| I | 1.02 | 1.26 | ||
| Mean | 0.96 | 1.62 |
We emphasize that the model (1)-(2) is minimal in its formulation, based on available data and potential limitations in parameter estimation. This model prioritizes effector T cell responses to SARS-CoV-2 in the host, leaving out other immunological mechanisms to . Note that this model has a big potential to evaluate therapeutic strategies, e.g., inhibiting viral replication or enhancing T cell reinforcements. For our analysis, we assume a positive constant value for each parameter.
2.1. Bifurcation parameter
We obtain the bifurcation parameter from the stability of the equilibrium point where . This equilibirum point is uniquely given by
| (5) |
To determine the stability, we compute the Jacobian matrix
| (6) |
Theorem 1
Let
(7) Thenis locally asymptotically stable foris non-hyperbolic forand is unstable (more precisely, a saddle) for. Furthermore,is a stable node ifbutandis a degenerate stable node when.
Proof
Evaluating the Jacobian matrix at i.e., we obtain two eigenvalues: and . Thus, is locally asymptotically stable for non-hyperbolic for and unstable for . Consider the trace and the determinant of which are
respectively. In the unstable case where we have hence is a saddle. If then
and if and only if . Therefore, is a stable node if but and is a degenerate stable node when . □
From now on, the eigenvalue will serve as our bifurcation parameter. Under any choice of parameter values, the value of is always bounded by
| (8) |
2.2. Positive equilibrium
We turn our attention to finding an equilibrium point where . The coordinates of satisfy the following equations:
| (9) |
| (10) |
Equation (10) necessitates . By applying (7) to express in terms of we solve Eq. (9) for and obtain
| (11) |
where
| (12) |
Lemma 1
Ifthen the following properties hold:
- (A)
if and only if.
- (B)
The quantitiesandhave equal sign.
Proof
Property (A) is a consequence of Eq. (11). We establish property (B) by taking signs through Eq. (12), and noting from the definition of that . □
To establish the existence and uniqueness of we establish that solves the equation where
| (13) |
Then is a rational function of where the graph of has the vertical asymptote and the horizontal asymptote . Furthermore,
| (14) |
and hence strictly decreases on its natural domain. Thus, has the unique root
| (15) |
By virtue of Eq. (7) and (12), we have and if and only if .
Lemma 2
Assumingwe haveif and only if.
Proof
We compute as
(16) where Eq. (7) and (12) provide . Since we take signs through Eq. (16) and conclude that if and only if . □
Lemma 3
Assumingthe functionadmits a unique root on the open intervalif and only if. This root is unique and lies in the open interval.
Proof
Recall Eq. (4), where and . Since by (14), we see that and strictly decreases. Therefore, has a root on if and only if i.e., by Lemma 2.
It follows from Eq. (15) that if and only if . Since is the root of i.e, we obtain
Thus, admits a root on the open interval ; the strict decreasing property of guarantees the uniqueness of this root. Finally, has no root in the open interval where and . Therefore, has a root in if and only if and this root is a unique value in . □
Theorem 2
Consider the positive equilibrium point. Then
(17) andis the unique solution ofin the open interval. Moreover,exists if and only ifand.
Proof
Equation (17) restates (11). According to both properties of Lemma 1, we have and equivalently only when . Assuming that Eq. (10) yields
(18) or by applying (17). Therefore, is the unique root of in the open interval . We conclude by Lemma 3 that exists with unique coordinates if and only if and . □
Assuming the explicit form (3) of we can transform the equation by way of scaling. Since strictly increases for we can express in terms of in a one-to-one correspondence given by
| (19) |
for and equivalently . Then we express as a function of : from equation (13) we have
where
Hence, we can solve for in the equation
| (20) |
by finding a root for the function
| (21) |
and then evaluating the corresponding with Eq. (19). One may prefer (21) over (20) to avoid evaluation at significantly large values.
Theorem 3
Suppose that the positive equilibrium pointexists, i.e.,and. Letanddenote the trace and determinant of Jacobian matrix. Thenand all eigenvalues ofhave negative real part; therefore,is locally asymptotically stable. Moreover,is a stable node fora degenerate stable node foror a stable spiral for.
Proof
Assuming the existence of we evaluate Eq. (6) at to get
This Jacobian matrix reduces to
by application of Eqs. (9) and (18). The trace and the determinant of is given by
Since both and are positive, and by (4), we have and . Therefore, the characteristic equation of the matrix namely
has all coefficients positive. Equivalently, all eigenvalues of have negative real part according to the Routh-Hurwitz criterion. Therefore, is locally asymptotically stable. If then the eigenvalues of are real and distinct, which determines as a stable node. The degenerate stable node case holds when from which the eigenvalues are real and equal. Finally, makes the eigenvalues become complex conjugates with negative real part (i.e., ), hence becomes a stable spiral. □
Remark
The change in qualitative behavior of depends on the value of in Theorem 3, which is
(22) We draw two observations:
- 1.
If or then by Eq. (17). Thus, Eq. (22) yields and becomes either a stable node or a degenerate stable node.
- 2.
For values of that are neither small nor sufficiently near increasing drives towards negative values and towards the stable spiral regime.
Regardless of the value of the proof in Theorem 3 asserts that the eigenvalues of the Jacobian matrix have negative real parts, hence they never cross the imaginary axis of the complex plane. This result prevents Hopf bifurcation with respect to .
2.3. Numerical example
Theorem 1, Theorem 2, and 3 characterize the existence and local stability of the equilibrium points and . We now complement these mathematical results with numerical simulations. Here, all parameters except take the values in the set of Table 1. Observe that has a one-to-one correspondence with namely by Eq. (7). Based on the maximum value of and in Table 1, we may impose the following restriction: . With our chosen parameter values, we generate our bifurcation diagram in Fig. 1 .
Fig. 1.
Bifurcation diagram for the model (1)-(2). Solid and dashed lines depict stable and unstable equilibrium points, respectively. The bifurcation occurs at (square marker). To generate the diagram, all values in the parameter set of Table 1 are used, except for that is obtained from via Eq. (7).
To expand on the remark made after Theorem 3 and explore the possibility of oscillations in the viral load, we consider the trace and the discriminant associated with as depicted in Fig. 2; the determinant is given by . Again, we choose set in Table 1 and let .
Fig. 2.
The trace and discriminant values associated with the equilibrium point . The blue line represents the negative trace of the Jacobian matrix and the red line represents the discriminant where is the determinant. Observe that at and approaches zero as increases. All parameters except take values from the set of Table 1, while . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3 depicts changes in the viral load trajectory with different values of . When increases and crosses the bifurcation value the viral load switches from being strictly decreasing to strictly increasing, corresponding to the exchange of stability between and (Fig. 1). The next bifurcation is at where the discriminant switches signs from positive to negative, and switches from being a stable node to a stable spiral. Fig. 3 shows the corresponding effect: the viral load begins to experience oscillations that dissipate over time. Further increasing reduces the magnitude of to zero, thereby increasing with . Moreover, the point approaches the positive -axis, and becomes a stable spiral that comes qualitatively close to being a center. Hence, the oscillations become more pronounced with a larger initial amplitude and a slower rate of dissipation, as confirmed numerically with the yellow and orange lines in Fig. 3. Another way to look at the long-term behavior of the model solution is a phase plane. Fig. 4 displays the solution curve for one of the cases in Fig. 3. This phase plane numerically validates the global asymptotic stability of ; we may also get the same result for when . The solution curve appears dense near which reflects the aforementioned oscillations with slow dissipation.
Fig. 3.
Changes in the viral load trajectory with . Each line represents a select value of . As increases from a negative value, the non-increasing viral load (black and blue dashed lines) experiences the following sequence of qualitative changes: strict increase to positive steady state value (blue and green solid lines), emergence of oscillations (yellow solid line), and increased amplitude of the oscillations (orange solid line). With reference to Fig. 2, the green solid line corresponds to the zero discriminant and a degenerate stable node for . All parameters except take values from the set of Table 1, while . All graphs are plot over a large time interval () to illustrate long-term behavior. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4.
A phase plane of the model (1)-(2) illustrating the global asymptotic stability of . The blue line represents the solution curve with initial point . The red circle represents the positive equilibrium point . All parameters except take values from the set of Table 1. This graph takes and . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
3. Sensitivity analysis
A sensitivity analysis of the model given by equations (1) and (2) is presented in this section. The aim is to compute the dynamical change of the model solution with respect to each parameter. Firstly, let us consider the general state equation of a nonlinear dynamical system:
| (23) |
where is continuous in and has continuous first partial derivatives with respect to and for all ; is the number of states and is the number of parameters. It is possible to know how the solution of Eq. (23) changes, with respect to parametric variation, that is:
| (24) |
by means of the solution of the so-called sensitivity function:
| (25) |
where and .
3.1. Numerical implementation
The in-host COVID-19 mathematical model has two states () defined as: and the initial conditions are: and . Let us define the set of the nine model parameters () as . The sensitivity function in Eq. (25) has states, corresponding to the entries of the matrix :
The matrices and in Eq. (25) are computed:
and
and evaluated considering the nominal parameters reported in [25], in the specific case of the fitted model with data for the patient . The sub index 0 stands for the nominal value of each parameter. Considering these last three matrices and initial conditions the sensitivity function (25) is solved. The solution of the sensitivity function provides the time variation of the model solutions regarding each parameter. Figs. 5 and 6 show the solution of the sensitivity function, that is, the effect of parametric variation on solutions and respectively. Fig. 7 shows the magnitude of parametric sensitivity of (top), and (bottom), respectively.
Fig. 5.
Sensitivity of considering nominal parameters of Patient .
Fig. 6.
Sensitivity of considering nominal parameters of Patient .
Fig. 7.
Maximum magnitudes of the sensitivity solutions for each parameter ( top, bottom).
Variations of initial conditions and parameters
In this second set of results, a variation on initial conditions of and are considered. Using the nominal initial condition and both initial conditions are varied such that the following conditions are met:
| (26) |
| (27) |
such that .
Fig. 8 shows considering a set of ten different initial conditions met condition (26); meanwhile, Fig. 9 depicts considering a set of ten different initial conditions met condition (27). With regard to parametric variation, Figs. 10 and 11 show and for ten different values of that is where is the nominal value of the parameter. Figs. 12 and 13 show parametric variation of for and respectively. Figs. 14 and 15 show variation of and when parameter is modified. Finally, Figs. 16 and 17 show variation of and regarding the parameter .
Fig. 8.
Solution varying initial condition .
Fig. 9.
Solution varying initial condition .
Fig. 10.
varying parameter .
Fig. 11.
varying parameter .
Fig. 12.
varying parameter .
Fig. 13.
varying parameter .
Fig. 14.
varying parameter .
Fig. 15.
varying parameter .
Fig. 16.
varying parameter .
Fig. 17.
varying parameter .
4. Discussion
The central theme of this work is a mathematical analysis of the model (1)-(2), one of the few models to describe the in-host dynamics of the SARS-CoV-2 disease. Among all in-host models considered in [25], this model provided the best fit to the viral load data in [26]. Since the parameters of this model characterize the effector T cell response to the pathogen, our stability and bifurcation analysis may help to understand how the immune system clears the pathogen.
Our analysis reveals that the parameter grouping
can drive the dynamics of our model (1)-(2). The value of allows comparison between ambient viral replication and clearance by T cells, represented by the per capita rates and respectively. By fixing the virus half-life and the homeostatic T cell count we observe that linearly increases with the viral replication rate and linearly decreases with the clearance rate . Thus, a biological meaning for is viral fitness. The parameter is also related to the within-host basic reproduction number
for which . Hence, is equivalent to which indicates an effective viral replication rate that outpaces T cell clearance.
Our main result is comparable to previous in-host infectious disease modeling [30]. In short, our model yields a unique locally asymptotically stable equilibrium point which is for (Theorem 1) and the positive viral load for (Theorems 2 and 3). This means that the viral load of a solution near approaches the corresponding viral load at . Thus, our local stability result agrees with the classic notion of a sufficient T cell response to eliminate the virus (large ), which may be counteracted with a reduced pool of T cells (small ). Meanwhile, the virus needs to achieve a fast replication (large ) to overcome T cell clearing; this is corroborated by the parameter estimates in Table 1 where . In contrast, a suppressed viral replication () is sufficient for halting the infection. Therefore, antivirals that can inhibit the replication of SARS-CoV-2 [31], [32] can play a central aspect during COVID-19.
The bifurcation diagram in Fig. 1 shows an increase in the viral load whenever is positive and increasing. Notably, the initial marginal gain of is sensitive to changes in near the bifurcation at which may suggest that SARS-CoV-2 infection is more severe once the viral replication overcomes the effector T cell clearance. Indeed, initially increases by four orders of magnitude from the bifurcation point. We determine from Fig. 1 that at (detection threshold) at and at . These values correspond to and due to .
The local asymptotic stability of suggests that a more rapid viral replication (large ) can elevate peak viral loads corresponding to a large which may be associated with mild and severe clinical features [16]. Comparing the different parameter sets in Table 1, we find a diverse range of : the smallest value () comes from set I, while the largest value () is from set F.
We should emphasize that the local asymptotic stability of only describes the behavior of solutions near . In Fig. 4, we demonstrated the global asymptotic stability of where a solution that does not begin near still approaches . Furthermore, the solution curves for large in Fig. 3 describe oscillations in the viral load as it approaches . Further analysis is need to verify these numerical examples with a Lyapunov function.
A more thorough bifurcation analysis requires and as additional bifurcation parameters, setting the stage for searching nontrivial dynamics. Both and do not affect viral replication and the effector T cell clearance characterized by . Instead, they are part of the T cell activation term . Moreover, the combined effects of varying and may influence the monotone and concave properties of by Eqs. (3) and (13), thereby influencing the marginal increase of with . For an initial exploration on this idea, we take the parameter setting from Fig. 18 , and then setting (this number, denoted was obtained by trial and error). Then we obtain a qualitatively different bifurcation diagram in Fig. 18, where the branch of the positive equilibrium point changes concavity. Here, initially experiences a slow increase with before progressing to higher orders of magnitude. We might call this peculiar observation a delayed saturation of the viral load, which is broken for either some sufficiently large or some new value of .
Fig. 18.
A bifurcation diagram for the model (1)–(2) illustrating delayed saturation of the viral load . All values in the parameter the set of Table 1 are used, except for and . The value of is obtained from in Eq. (7), while is assumed the value . We remark that this phenomenon could only occur when and are sufficiently near and .
The asymptotic stability of the positive equilibrium (Theorem 3) means that the virus is expected to reach persistent levels. However, long-term persistence of the virus is associated with chronic diseases like HIV. The 2019 coronavirus disease is acute, where viral peaks are expected to occur for limited time.
Hence, it is relevant to ask what parameters can make implying a theoretical undetected level of the virus. To this end, we recall that is the root of in the open interval (Lemma 3), where is the positive root of ; see Eq. (15). Thus, the viral load is below the detection threshold when . However, this condition only applies to very small with .
Alternatively, we may consider the explicit form of Eq. (3) where and the definition of in (13). Note that reducing allows to saturate for small values of while the value of is inversely proportional to . Therefore, the combined effect of reduced T cell tolerance to the virus (small ) and a faster T cell activation (large ) could play a key role in reducing the viral load, with the goal of having for all not exceeding a physiological bound.
The trace and determinant values associated with provide another perspective to viral load peaks. Assuming parameter values from the set Mean in Table 1 and computing from we find that is already a stable spiral for above a small positive value (0.0153), where the discriminant is negative (Fig. 2) and viral load oscillations begin to emerge. As the solution trajectories in Fig. 3 indicate, the viral load oscillations become more pronounced with slower dissipation as continues to increase; this effect is due to the qualitative behavior of approaching the non-hyperbolic center in the trace-determinant plane. In particular, the viral load experiences a larger initial local maximum (peak) and a smaller succeeding local minimum.
From the observations above, we draw the following interpretations. SARS-CoV-2 peak may have a determinant effect once the pathogen overcomes T cell responses (i.e. when crosses some small positive threshold). However, it may be necessary for the virus to replicate fast (large ) to experience a significant initial viral peak followed by reduction to levels below detection. Speaking mainly on theoretical terms, if we allow SARS-CoV-2 infection to continue over weeks, then the virus may possible re-emergence at an intermediate stage. Studies that support the idea of reinfection or fluctuating viral loads may agree with the findings here.
On a more technical side, we remark that the generation of our bifurcation diagrams entailed computational challenges. The sensitivity of near required values of to be concentrated around the bifurcation value. For values of evaluation of requires first evaluating with the risk of losing numerical accuracy for large . This motivated us to derive the auxiliary function
in Eq. (21). The root of in the subset of the open interval corresponds bijectively with now given by
Conversely, the viral load at the positive equilibrium point determines the corresponding T cell activation rate, .
The model (1)–(2) focuses on the interaction between SARS-CoV-2 and effector cells, but other important factors may play key roles during infection. Regulatory components of the immune system may be important for considering how T cells clear a limited portion of the pathogen [33]. Finally, we may employ a multiscale modeling framework to evaluate how the severity of in-host infection can determine effective between-host transmission [30].
CRediT authorship contribution statement
Alexis Erich S. Almocera: Bifurcation Analysis, Writing - original draft. Griselda Quiroz: Sensitivity analysis, Writing - original draft. Esteban A. Hernandez-Vargas: Conceptualization, Resources, Supervision, Writing - review & editing.
Declaration of Competing Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgements
This research was funded Universidad Nacional Autonoma de Mexico (UNAM) from grant PAPIIT-UNAM, CONACYT, and the Alfons und Gertrud Kassel-Stiftung.
References
- 1.Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., et al. The species severe acute respiratory syndrome-Related coronavirus: classifying 2019-ncov and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.European CDC. Situation update worldwide, as of 14 April 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases Library Catalog: www.ecdc.europa.eu; 2020.
- 6.World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports Library Catalog: www.who.int; 2020.
- 7.Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases. 2020;0(0) doi: 10.1016/S1473-3099(20)30120-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Anderson R.M., Heesterbeek H., Klinkenberg D., Hollingsworth T.D. How will country-based mitigation measures influence the course of the COVID-19 epidemic? The Lancet. 2020;395(10228):931–934. doi: 10.1016/S0140-6736(20)30567-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ferguson N.M., Laydon D., Nedjati-Gilani G., Imai N., Ainslie K., Baguelin M., et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand2020;20.
- 10.Heesterbeek H., Anderson R.M., Andreasen V., Bansal S., De Angelis D., Dye C., et al. Modeling infectious disease dynamics in the complex landscape of global health. Science (New York, NY) 2015;347(6227):aaa4339. doi: 10.1126/science.aaa4339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen W.-H., Strych U., Hotez P.J., Bottazzi M.E. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020 doi: 10.1007/s40475-020-00201-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 doi: 10.1001/jama.2020.6019. [DOI] [PubMed] [Google Scholar]
- 13.Oh M.-d., Park W.B., Choe P.G., Choi S.-J., Kim J.-I., Chae J., et al. Viral load kinetics of MERS coronavirus infection. N top N Engl J Med. 2016;375(13):1303–1305. doi: 10.1056/NEJMc1511695. [DOI] [PubMed] [Google Scholar]
- 14.Peiris J.S.M., Chu C.M., Cheng V.C.C., Chan K.S., Hung I.F.N., Poon L.L.M., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767–1772. doi: 10.1016/s0140-6736(03)13412-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020:1–10. doi: 10.1038/s41586-020-2196-x. [DOI] [PubMed] [Google Scholar]
- 16.Liu Y., Yan L.-M., Wan L., Xiang T.-X., Le A., Liu J.-M., et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infectious Diseases. 2020;20(6):656–657. doi: 10.1016/S1473-3099(20)30232-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Liu J., Li S., Liu J., Liang B., Wang X., Li W., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55(102763) doi: 10.2139/ssrn.3539682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y., Hafezi M., Chia A., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020 doi: 10.1038/s41586-020-2550-z. [DOI] [PubMed] [Google Scholar]
- 19.Tan W., Lu Y., Zhang J., Wang J., Dan Y., Tan Z., et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv. 2020 doi: 10.1101/2020.03.24.20042382. [DOI] [Google Scholar]
- 20.Lake M.A. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20(2):124–127. doi: 10.7861/clinmed.2019-coron. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Nikolich-Zugich J., Knox K.S., Rios C.T., Natt B., Bhattacharya D., Fain M.J. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience. 2020 doi: 10.1007/s11357-020-00186-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Li C., Xu J., Liu J., Zhou Y. The within-host viral kinetics of SARS-CoV-2. Mathematical Biosciences and Engineering. 2020;17(4):2853–2861. doi: 10.1101/2020.02.29.965418. [DOI] [PubMed] [Google Scholar]
- 23.Oh M.-d., Park W.B., Choe P.G., Choi S.-J., Kim J.-I., Chae J., et al. Viral load kinetics of MERS coronavirus infection. N top N Engl J Med. 2016;375(13):1303–1305. doi: 10.1056/NEJMc1511695. [DOI] [PubMed] [Google Scholar]
- 24.Pan F., Ye T., Sun P., Gui S., Liang B., Li L., et al. Time course of lung changes in chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020:200370. doi: 10.1148/radiol.2020200370. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Hernandez-Vargas E.A., Velasco-Hernandez J.X. In-host mathematical modelling of COVID-19 in humans. Annu Rev Control. 2020 doi: 10.1016/j.arcontrol.2020.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Woelfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Mueller M.A., et al. Preprint. Infectious Diseases (except HIV/AIDS); 2020. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. [DOI] [Google Scholar]
- 27.Callaway E. Coronavirus vaccines: Five key questions as trials begin. Nature. 2020;579(7800) doi: 10.1038/d41586-020-00798-8. [DOI] [PubMed] [Google Scholar]; 481–481
- 28.Zhang J., Zeng H., Gu J., Li H., Zheng L., Zou Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel) 2020;8(2):153. doi: 10.3390/vaccines8020153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Boianelli A., Nguyen V., Ebensen T., Schulze K., Wilk E., Sharma N., et al. Modeling influenza virus infection: a roadmap for influenza research. Viruses. 2015;7(10):5274–5304. doi: 10.3390/v7102875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Almocera A.E.S., Nguyen V.K., Hernandez-Vargas E.A. Multiscale model within-host and between-host for viral infectious diseases. J Math Biol. 2018;77(4):1035–1057. doi: 10.1007/s00285-018-1241-y. [DOI] [PubMed] [Google Scholar]
- 31.Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:104787. doi: 10.1016/j.antiviral.2020.104787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Touret F., Gilles M., Barral K., Nougairede A., Decroly E., de Lamballerie X., et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. bioRxiv. 2020 doi: 10.1101/2020.04.03.023846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Almocera A.E.S., Hernandez-Mejia G., Parra-Rojas C., Hernandez-Vargas E.A. The trichotomy of pneumococcal infection outcomes in the Host. Commun Nonlinear Sci Numer Simul. 2019;73:1–13. doi: 10.1016/j.cnsns.2019.01.025. [DOI] [Google Scholar]


















